The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
@article{HBSN108292, author = {Sabine Lieb and Sebastian Ebel and Daniel Seehofer and Thomas Berg and Florian van Bömmel}, title = {The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab}, journal = {Hepatobiliary Surgery and Nutrition}, volume = {12}, number = {1}, year = {2023}, keywords = {}, abstract = {}, issn = {2304-389X}, url = {https://hbsn.amegroups.org/article/view/108292} }